Lexaria Enters Definitive License Agreement with California Cannabis Beverage Manufacturer

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / April 25, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with GP Holdings LLC. ("GP") whereby Lexaria is…

Lexaria Announces Human Clinical Study on CBD Absorption Underway

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / April 23, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce that it has commenced a clinical study in Europe to evaluate the cardiovascular and cognitive…

Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / April 17, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce positive topline results upon completion of its first ingestible nicotine in vivo (animal) absorption study.…

Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates its Expanding Patent Portfolio

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia -/ TheNewswire / April 11, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received another new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing…

Lexaria Announces Exercises of Existing Warrants, Enters Investor Relations Agreement

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / March 23, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces warrant transactions. Lexaria announces it has received US$ 220,000 from the exercise of warrants previously granted. The Company has received for exercise a…

Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for “Composition of Matter” Cannabinoid Delivery

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / March 22, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing…

Lexaria Files New Patent Application for Enhanced Transdermal Delivery System

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / March 20, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce it has filed a new patent application with the United States Patent and Trademark Office…

Lexaria Begins Nicotine Absorption Study

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / March 14, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce that it has commenced its first nicotine in vivo (animal) absorption and tolerability study. The…

Lexaria Bioscience Corp. Completes Successful Skin Absorption Study

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / March 13, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce it has completed the world’s first study evaluating DehydraTECHTM used in a topical cream formulation…

Lexaria Enters Licensing Agreement with Cannabis Edibles Infusion Company

Tickers: XCNQ:LXX, XOTC:LXRP, PINX:LXRPTags: None Kelowna, British Columbia / TheNewswire / February 27, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with Los Angeles-based, privately-held Biolog, Inc. ("Biolog") whereby…